Risk‐of‐bias VISualization (robvis): An R package and Shiny web app for visualizing risk‐of‐bias assessments

McGuinness, Luke A; Higgins, Julian P T

doi:10.1002/jrsm.1411

Cited by 2,237 publications

(1,609 citation statements)

References 23 publications

Supporting

Mentioning

1,337

Contrasting

Unclassified

Order By: Relevance

“…69 The Robvis web app will be employed for visualizing risk-of-bias assessments plots. 70 Any disagreements in the ratings will be resolved by discussion.…”

Section: Confidence In Cumulative Findings and Risk Of Biasmentioning

confidence: 99%

<p>A Comprehensive Scoping Review Protocol of Using Living Labs to Explore Needs and Solutions for Older Adults with Dementia</p>

Verloo¹,

Lorette²,

Rocha³

et al. 2020

SHTT

View full text Add to dashboard Cite

Background: A significant number of living labs (LLs) have been developed across Europe and beyond. A fraction of those LLs have established a new approach to maintaining and studying the health, autonomy, and well-being of older adults with dementia. LLs interact with a broad set of stakeholders, including students, academic institutions, private companies, healthcare organizations, and patient representative bodies -even with other LLs. It is crucial to identify what kinds of co-creations should be done and how they can be facilitated through LLs. Despite a growing body of literature, a clear overview and understanding of the services, research, and clinical activities developed in different LL settings for older adults with dementia are still lacking. Aim: The aim is to scope publications examining all types of LL activities which explore the needs of and suggest solutions for older adults with dementia, whether they live in the community or long-term healthcare facilities. Methods: The bibliographic databases to be searched will include Embase.com, Medline Ovid SP, Pubmed (not medline [sb]) and Web of Science, without language or date restrictions. We will examine the bibliographies of all relevant articles found, conduct a search for unpublished studies, and perform a handsearch in relevant journals associated with LLs involved in healthcare (Electronic Journal for Virtual Organization and Networks, Technology Innovation Management Review, Journal of Engineering and Technology Management). We will consider publications in English, French, and German. Results: Bibliographic database searches will be completed in March 2020, retrieved articles will be screened, and the entire study is expected to be completed by December 2020. Discussion: This comprehensive scoping review will provide a global indication of the types and extent of LL activities aimed at older adults with dementia, whether they live in the community or in long-term care facilities.

show abstract

“…69 The Robvis web app will be employed for visualizing risk-of-bias assessments plots. 70 Any disagreements in the ratings will be resolved by discussion.…”

Section: Confidence In Cumulative Findings and Risk Of Biasmentioning

confidence: 99%

<p>A Comprehensive Scoping Review Protocol of Using Living Labs to Explore Needs and Solutions for Older Adults with Dementia</p>

Verloo¹,

Lorette²,

Rocha³

et al. 2020

SHTT

View full text Add to dashboard Cite

show abstract

“…In ROBINS-I, studies were assessed for bias as a result of confounding, selection of participants, classi cation and deviation from intended interventions, missing data, outcome measurement and selective reporting of results and were assessed as Critical, Serious, Moderate, Low, No information. Robvis (visualization tool) [13] was used for synthesis of plots for risk of bias. [13] For assessment of publication bias, funnel plot was generated along with Egger's regression test.…”

Section: Quality Assessment Of Studiesmentioning

confidence: 99%

“…Robvis (visualization tool) [13] was used for synthesis of plots for risk of bias. [13] For assessment of publication bias, funnel plot was generated along with Egger's regression test.…”

Section: Quality Assessment Of Studiesmentioning

confidence: 99%

Efficacy and Safety of Tocilizumab in the Treatment of SARS-CoV-2: A Systematic Review and Meta-analysis

Singh

Khera

Chugh

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Cytokine storm is the main cause of mortality in COVID-19. Tocilizumab, an IL-6 inhibitor, is being tested for its therapeutic potential in this condition. To evaluate the efficacy and safety of Tocilizumab in comparison to Standard therapy in the treatment of COVID-19 in adult patients. Methods: Using Medline (via PubMed), The Cochrane Central Register of Controlled Trials, preprint server (medRxiv) and clinicaltrials.gov, a final search was conducted on 26th June 2020. All types of clinical studies (prospective or retrospective cohort studies, observational case-control studies, clinical trials) aiming to evaluate the role of Tocilizumab in the treatment of patients with COVID-19 were considered eligible for this systematic review. Tocilizumab was considered as the intervention group and standard of care or drugs other than tocilizumab as control group. Meta-analysis was performed by Cochrane review manager 5 (RevMan) version 5.3. For quality assessment, ROBINS-I (The Risk Of Bias In Non-randomised studies – of Interventions) assessment tool for observational studies was used. The overall quality of evidence for each of the outcomes was assessed using the GRADE Pro GDT. Results: Out of 362 records identified, 13 studies were included in qualitative and quantitative analysis. Tocilizumab treatment was associated with 46% decrease in probability of mortality rate [Adjusted HR = 0.54 (95% CI = 0.44-0.68), p<0.00001; I2=74%] and 66% odds decrease in progression of disease [OR = 0.34 (95% CI = 0.21 – 0.55), p<0.0001; I2=76%] compared to control. However, there was no difference in hospital discharge [OR = 1.35 (95% CI = 0.84 – 2.18), p=0.22; I2=22%] and clinical improvement [OR = 1.02 (95% CI = 0.61 – 1.69), p=0.95; I2=84%] with tocilizumab. There was statistically significant increase in risk of secondary bacteraemia [OR = 2.75 (95% CI = 1.86 – 4.06), p< 0.00001] and superinfections [OR = 2.93 (95% CI = 1.92 – 4.46), p< 0.00001].Conclusions: With current evidence on efficacy and safety of tocilizumab, we recommend use of tocilizumab treatment for moderate to severe COVID-19 patients caused by SARS-CoV-2, along with caution for superinfections.Systematic review registration: PROSPERO registration number: CRD42020189517

show abstract

“…The NMAs were carried out using the netmeta version 1.2-1 package [26]. The risk of bias was visualized using the robvis version 0.3.0 package [27]. The meta-analysis was performed using the meta version 4.12-0 package [28].…”

Section: Statistical Softwarementioning

confidence: 99%

Blue-wavelength Light Therapy for Post-traumatic Brain Injury Sleepiness, Sleep Disturbance, Depression, Fatigue: A Systematic Review and Network Meta-analysis

Srisurapan

Samakarn

Kamklong

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: We aimed to determine the efficacy of blue-wavelength light therapy (BWLT) for post-traumatic brain injury (TBI) sleepiness, sleep disturbance, depression, and fatigue.Methods: We searched six databases for randomized controlled trials of BWLT for adults with a history of TBI. Outcomes of interest included sleepiness, sleep disturbance, depression, or fatigue. We conducted random-effect frequentist network meta-analyses (NMA) to compare the efficacy and a pairwise meta-analysis to examine the dropout rates.Results: We included four randomized controlled trials that compared BWLT, amber light therapy, and no light therapy. BWLT was significantly superior in reducing depression as compared to amber light therapy (SMD = 0.57, 95% CI = 0.04 to 1.10) and no light therapy (SMD = 0.81, 95% CI = 0.20 to 1.43). BWLT was also significantly superior in reducing fatigue as compared to amber light therapy (SMD = 1.00, 95% CI = 0.14 to 1.86) and no light therapy (SMD = 1.09, 95% CI = 0.41 to 1.76). There was no significant heterogeneity of depression and fatigue data (I2 = 0% for both). The relative risk of dropout rates (95% CI) shows no significant difference between BWLT and amber light therapy groups (RR = 3.72, 95% CI = 0.66 to 21.34, I2 = 0%).Conclusion: BWLT may be effective for post-TBI depression and fatigue. Due to the risks of bias and the inability to exclude publication bias among included studies, the current evidence remains insufficient to support the clinical application of BWLT for post-TBI depression and fatigue. Protocol registration: The protocol of this systematic review is available at Open Science Framework (https://osf.io/yf2qe/).

show abstract

Risk‐of‐bias VISualization (robvis): An R package and Shiny web app for visualizing risk‐of‐bias assessments

Cited by 2,237 publications

References 23 publications

<p>A Comprehensive Scoping Review Protocol of Using Living Labs to Explore Needs and Solutions for Older Adults with Dementia</p>

<p>A Comprehensive Scoping Review Protocol of Using Living Labs to Explore Needs and Solutions for Older Adults with Dementia</p>

Efficacy and Safety of Tocilizumab in the Treatment of SARS-CoV-2: A Systematic Review and Meta-analysis

Blue-wavelength Light Therapy for Post-traumatic Brain Injury Sleepiness, Sleep Disturbance, Depression, Fatigue: A Systematic Review and Network Meta-analysis

Contact Info

Product

Resources

About